introduction When we were planning the present study in 2007, there was no standard chemotherapy for advanced gastric cancer (AGC) in Japan [1] . Three large randomized phase III studies comparing S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) with S-1 plus another cytotoxic agent as first-line chemotherapy for AGC were ongoing [2] [3] [4] . Patients who did not respond to first-line S-1-based chemotherapy often received a taxane-or irinotecan (Yakult Honsha Co., Ltd., Tokyo, Japan and Daiichi Sankyo Co., Ltd., Tokyo, Japan)-alone as second-line chemotherapy, mainly because these drugs were not used for first-line treatment.
In Japan, irinotecan-alone has been approved for the treatment of AGC since 1995. The approved dose of irinotecan is 150 mg/m 2 every 2 weeks or 100 mg/m 2 weekly. These doses are lower than the levels used in Western countries, and irinotecan cannot be used in a dose of 350 mg/m 2 every 3 weeks. S-1 plus irinotecan has been reported to have a higher response rate than irinotecan-alone (54%versus 18%) [5, 6] . S-1 plus irinotecan has been widely used as second-line treatment in patients with AGC resistant to first-line S-1-based chemotherapy [7] .
Combining S-1 with irinotecan is supported by the results of in vitro studies, showing that S-1-resistant gastric cancer cell lines have increased activity of the target enzyme thymidylate synthase and that concomitant treatment with irinotecan decreases such activity [8] . In vivo studies have demonstrated that combining S-1 with irinotecan enhances the antitumor activity of S-1 against S-1-resistant cell lines [9] . Moreover, S-1 plus irinotecan is effective even against tumors with high thymidylate synthase mRNA expression [10] .
To date, however, no randomized clinical trial has confirmed whether the consecutive use of S-1 as second-line treatment is beneficial after the failure of first-line S-1-based chemotherapy in AGC.
The present study was designed to test the hypothesis that second-line treatment with S-1 plus irinotecan would prolong survival when compared with irinotecan-alone after the failure of first-line S-1-based chemotherapy in patients with AGC.
methods study design
The Japan Clinical Cancer Research Organization (JACCRO) GC-05 study was a multicenter, prospective, randomized open-label trial. We employed a phase II and III design for the probability of rejecting the null hypothesis of phase III. The study was carried out in accordance with the Declaration of Helsinki and the Ethical guidelines for clinical studies in Japan. The protocol was approved by the ethics committees of JACCRO and of each participating center before initiation of enrollment. An Independent Data Monitoring Committee (IDMC) reviewed all efficacy and safety data.
patients
Eligible patients had to have a histologically confirmed diagnosis of gastric or esophagogastric junction adenocarcinoma and confirmed disease progression on imaging studies after first-line treatment with S-1-alone, S-1 plus cisplatin (Bristol-Myers Squibb, Tokyo, Japan and Nippon Kayaku Co., Ltd., Tokyo, Japan), or S-1 plus docetaxel (Sanofi K.K., Tokyo, Japan) (excluding S-1 plus irinotecan). Patients who had received S-1-based regimens as adjuvant chemotherapy were excluded. Other eligibility criteria were an age of 20 years or older, an Eastern Cooperative Oncology Group performance status of 0 or 1, Eight patients assigned to the S-1 plus irinotecan group were found to be ineligible and excluded for the following reasons: ileus (N = 2), deterioration of liver function (N = 2), decreased and increased white-cell count (N = 2), worsening of general condition before the study treatment and severe S-1-related adverse events during first-line therapy (N = 1), and previous adjuvant chemotherapy with S-1 (N = 1). Three patients assigned to the irinotecan alone group were excluded for the following reasons: icterus (N = 1), previous adjuvant chemotherapy with S-1 (N = 1), and withdrawal of informed consent (N = 1). These patients were excluded from the full analysis set in each group. The patient who had previously received adjuvant chemotherapy with S-1 was added to the safety analysis set. 
statistical considerations
The primary end point of the phase II part of the study was the disease progression rate at 6 weeks, with a threshold value of 60% (90% confidence interval [CI], two-sided alpha of 0.10) in the first 60 patients. The primary end point of the phase III part was overall survival (OS), defined as the time from randomization to death from any cause. Secondary end points were progression-free survival (PFS), response rate, safety, and the proportion of patients who received third-line chemotherapy. Tumors were measured every 6 weeks by the investigators at each participating center until the onset of progressive disease. An extramural review committee assessed all images obtained in the phase II part of the study according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. We used the Kaplan-Meier method to calculate survival curves, and the stratified log-rank test to make comparisons. We estimated that the median OS would be 7 months in the S-1 plus irinotecan group and 5 months in the irinotecan-alone group on the basis of the results of several Japanese studies of second-line chemotherapy in patients with AGC [11, 12] . Consequently, according to the Schoenfeld method [13] , 300 patients (including the phase II part) were estimated to be needed for the study to have an 80% power to detect a difference in OS between the treatment groups with a two-sided alpha value of 0.05, assuming an enrollment period of 2 years, a follow-up period of 2 years, and a 10% exclusion rate due to ineligibility. We planned an interim analysis when 100 events had occurred, using an O'Brien-Fleming-type alpha spending function.
results patient disposition and characteristics
Between February 2008 and May 2011, 304 patients were enrolled at 68 centers in Japan. A total of 153 patients were assigned to the S-1 plus irinotecan group, and 151 were assigned to the irinotecan-alone group. The full analysis set comprised 293 patients (145 in the S-1 plus irinotecan group and 148 in the irinotecan-alone group). Efficacy was analyzed in these patients, and safety was analyzed in 294 patients (including one patient in the irinotecan-alone group who was found to be ineligible after treatment began; Figure 1 ). The baseline characteristics were well balanced (Table 1) .
phase II part
In the phase II part of the study, 30 patients were assigned to the S-1 plus irinotecan group, and 32 were assigned to the irinotecanalone group. The disease progression rate at 6 weeks was 43.3% Figure 2A ). The hazard ratio (HR) for death was 0.99 (95% CI 0.78-1.25). Median PFS was nearly identical in the S-1 plus irinotecan group and irinotecan-alone group (3.8 months [IQR 1.9-6.6]versus 3.4 months [IQR 1.6-5.3]; P = 0.16; Figure 2B ). The HR for disease progression or death was 0.85 (95% CI 0.67-1.07).
Of the 118 patients in the S-1 plus irinotecan group who had measurable lesions, no patient had a complete response, and 9 had a partial response for a response rate of 7.6% (95% CI 2.8-12.4). Among the 122 patients in the irinotecan-alone group, no patient had a complete response, and 9 had a partial response for a response rate of 7.4% (95% CI 2.7-12.0). The response rate did not differ between the two groups ( Table 2 ).
safety
The incidences of grade 3 or higher leukopenia (24.1% versus 8.1%, P < 0.01) and of febrile neutropenia (8.3% versus 0.7%, P < 0.01) were significantly higher in the S-1 plus irinotecan group than in the irinotecan-alone group (Table 3) . There were two treatment-related deaths in the irinotecan-alone group.
third-line chemotherapy
Similar proportions of patients in the two groups received thirdline chemotherapy (S-1 plus irinotecan group, 84 of 145 [57.9%] patients; irinotecan-alone group, 91 of 148 [61.5%] patients). Among the patients who received third-line chemotherapy in the respective treatment groups, the regimen comprised weekly paclitaxel (Bristol-Myers Squibb, Tokyo, Japan) in 43 (51.2%) patients in the S-1 plus irinotecan group and 47 (51.6%) patients in the irinotecan-alone group, docetaxel-alone in 13 (15.5%) patients in the S-1 plus irinotecan group, 10 (11.0%) patients in the irinotecan-alone group, and S-1 plus docetaxel in 7 (8.3%) patients in the S-1 plus irinotecan group and 14 (15.4%) patients in the irinotecan-alone group.
subset analysis
The benefits of the combination treatment were not seen in any of the investigated subgroups (Figure 3 ).
discussion
Recently, S-1 plus cisplatin combination therapy has been employed as first-line therapy for AGC on the basis of the results of the SPIRITS trial [2] . On the basis of a post hoc analysis of the START trial, S-1 combined with docetaxel has been regarded as an option for first-line treatment in patients with AGC, particularly those who have compromised renal function or who wish to receive chemotherapy on an outpatient basis [4] . However, in the GC0301/TOP-002 trial, S-1 plus irinotecan was not significantly superior to S-1-alone [3] .
In the three randomized controlled studies described above, >70% of the patients received second-line chemotherapy after the failure of initial chemotherapy for AGC. Second-line treatment plays a very important role in prolonging survival. Survival time after tumor progression was longer than the PFS in these trials. Single agents such as paclitaxel, docetaxel, or irinotecan are often used as second-line treatment, because these drugs are not included in the standard first-line regimen of 5-fluorouracil plus a platinum compound. However, on the basis of basic research on S-1-resistant gastric cancer cell lines and retrospective analyses [7] [8] [9] , we hypothesized that the consecutive use of S-1 combined with irinotecan as second-line treatment might prolong survival after the failure of first-line S-1-based chemotherapy.
Recently, the German AIO trial reported that second-line chemotherapy with irinotecan significantly prolongs OS when compared with best supportive care (BSC) in AGC [14] , a Korean phase III trial reported that irinotecan or docetaxel prolongs survival when compared with BSC [15] , and the Cougar-02 trial found that docetaxel is associated with better survival than active symptom control [16] . The results of all three of these studies indicate that second-line chemotherapy significantly improves OS when compared with BSC in patients with AGC.
The WJOG4007 phase III trial reported no significant difference between irinotecan and weekly paclitaxel in patients with AGC refractory to combination chemotherapy with a fluoropyrimidine plus a platinum compound [17] . On the basis of these results, irinotecan and taxanes have become important drugs for the second-line treatment of AGC refractory to first-line chemotherapy with S-1 (fluoropyrimidine) plus a platinum compound. In our study, 60% of patients received third-line chemotherapy, and 78% of patients received a taxane-alone or a taxane-based regimen. To prolong the survival of patients with AGC, it is most important to use all four of the following types of drugs: fluoropyrimidines (S-1), platinum compounds (cisplatin and oxaliplatin), irinotecan, and taxanes.
However, our study provided no evidence that S-1 plus irinotecan was more clinically beneficial than irinotecan-alone as second-line treatment in patients with AGC refractory to firstline S-1-based chemotherapy. Moreover, the incidences of adverse events such as grade 3 or higher leukopenia and febrile neutropenia were significantly higher in the S-1 plus irinotecan group than in the irinotecan-alone group, even though the total administered dose of irinotecan was lower in the former than in the latter (S-1 plus irinotecan group 744 mg versus irinotecanalone group 1185 mg). Figure 3 . Forest plot of subgroup analysis of overall survival in the irinotecan plus S-1 group when compared with the irinotecan-alone group. ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoembryonic antigen; non-sensitive: SD, stable disease; PD, progressive disease; or NE, not evaluable; sensitive: CR, complete response; or PR, partial response. disclosure MF has received consulting fees from Taiho Pharmaceutical Co., Ltd and honoraria from Taiho. KN has received research funding from Taiho and Yakult Honsha Co., Ltd and honoraria from Chugai Pharma Co., Ltd and Ajinomoto Co., Ltd. AT has received honoraria from Taiho, Daiichi Sankyo Co., Ltd, Merck Serono Japan Co., Ltd, and Chugai Pharma. YK has received honoraria from Taiho and Chugai Pharma. WI has received consulting fees from Merck Serono, Daiichi Sankyo and Zeria Pharma Co., Ltd, research funding from Taiho and Takeda Co., Ltd, and honoraria from Taiho, Merck Serono, Bristol-Myers Squibb Co., Ltd, Chugai Pharma, Bayer Co., Ltd, Daiichi Sankyo, and Takeda. MT has received consulting fees from Taiho, Astra Zeneca Co., Ltd, Hisamitsu Pharma Co., Ltd, and Kyorin Pharma Co., Ltd. All remaining authors have declared no conflicts of interest.
references
